MX385975B - Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1. - Google Patents
Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1.Info
- Publication number
- MX385975B MX385975B MX2018009952A MX2018009952A MX385975B MX 385975 B MX385975 B MX 385975B MX 2018009952 A MX2018009952 A MX 2018009952A MX 2018009952 A MX2018009952 A MX 2018009952A MX 385975 B MX385975 B MX 385975B
- Authority
- MX
- Mexico
- Prior art keywords
- acetylcholine receptor
- positive allosteric
- allosteric modulators
- muscarinic acetylcholine
- compounds
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 102000018154 Muscarinic acetylcholine receptor M1 Human genes 0.000 title 1
- 108050007299 Muscarinic acetylcholine receptor M1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000017927 CHRM1 Human genes 0.000 abstract 1
- 101150073075 Chrm1 gene Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296012P | 2016-02-16 | 2016-02-16 | |
| US201662402438P | 2016-09-30 | 2016-09-30 | |
| PCT/US2017/018140 WO2017143041A1 (en) | 2016-02-16 | 2017-02-16 | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018009952A MX2018009952A (es) | 2018-11-29 |
| MX385975B true MX385975B (es) | 2025-03-18 |
Family
ID=59626207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009952A MX385975B (es) | 2016-02-16 | 2017-02-16 | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11111251B2 (enExample) |
| EP (1) | EP3416639B1 (enExample) |
| JP (1) | JP2019504901A (enExample) |
| KR (1) | KR20180110132A (enExample) |
| CN (1) | CN109069491A (enExample) |
| AU (1) | AU2017221404A1 (enExample) |
| BR (1) | BR112018016689A2 (enExample) |
| CA (1) | CA3014791A1 (enExample) |
| CL (1) | CL2018002335A1 (enExample) |
| EA (1) | EA201891854A1 (enExample) |
| IL (1) | IL261058A (enExample) |
| MA (1) | MA44253A (enExample) |
| MX (1) | MX385975B (enExample) |
| PH (1) | PH12018501731A1 (enExample) |
| WO (1) | WO2017143041A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60875B1 (sr) * | 2016-09-02 | 2020-11-30 | Suven Life Sciences Ltd | Pozitivni alosterni modulatori muskarinskog m1 receptora |
| EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
| SI3643718T1 (sl) | 2017-06-20 | 2023-11-30 | Takeda Pharmaceutical Company Limited | Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1 |
| CA3068209A1 (en) * | 2017-06-20 | 2018-12-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| ES3064093T3 (en) | 2017-10-20 | 2026-04-22 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| SG11202003471XA (en) * | 2017-10-27 | 2020-05-28 | Suven Life Sciences Ltd | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators |
| AU2018360581A1 (en) | 2017-10-31 | 2020-06-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US11414406B2 (en) | 2018-02-02 | 2022-08-16 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019241467A1 (en) * | 2018-06-13 | 2019-12-19 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US12162864B2 (en) | 2018-09-28 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| JP7443238B2 (ja) | 2018-09-28 | 2024-03-05 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| WO2020086864A1 (en) | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| ES3057371T3 (en) | 2019-10-04 | 2026-03-02 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4608079A (en) | 1983-08-02 | 1986-08-26 | American Cyanamid Company | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| AU759875B2 (en) | 1999-03-09 | 2003-05-01 | Pharmacia & Upjohn Company | 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents |
| RU2269523C2 (ru) | 2000-04-28 | 2006-02-10 | Акадиа Фармасьютикалз, Инк. | Мускариновые агонисты |
| EP1432707B1 (en) | 2001-10-02 | 2012-03-28 | Pharmacia & Upjohn Company LLC | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| PH12012501222A1 (en) * | 2009-12-17 | 2012-11-05 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
| US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
| WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN105793259A (zh) | 2014-01-22 | 2016-07-20 | 豪夫迈·罗氏有限公司 | 氟-萘基衍生物 |
| JP6571077B2 (ja) | 2014-06-13 | 2019-09-04 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| RS60875B1 (sr) | 2016-09-02 | 2020-11-30 | Suven Life Sciences Ltd | Pozitivni alosterni modulatori muskarinskog m1 receptora |
-
2017
- 2017-02-16 EA EA201891854A patent/EA201891854A1/ru unknown
- 2017-02-16 JP JP2018561928A patent/JP2019504901A/ja active Pending
- 2017-02-16 MX MX2018009952A patent/MX385975B/es unknown
- 2017-02-16 CA CA3014791A patent/CA3014791A1/en active Pending
- 2017-02-16 AU AU2017221404A patent/AU2017221404A1/en not_active Abandoned
- 2017-02-16 CN CN201780023438.3A patent/CN109069491A/zh active Pending
- 2017-02-16 US US15/998,899 patent/US11111251B2/en active Active
- 2017-02-16 WO PCT/US2017/018140 patent/WO2017143041A1/en not_active Ceased
- 2017-02-16 BR BR112018016689A patent/BR112018016689A2/pt not_active IP Right Cessation
- 2017-02-16 KR KR1020187026643A patent/KR20180110132A/ko not_active Withdrawn
- 2017-02-16 MA MA044253A patent/MA44253A/fr unknown
- 2017-02-16 EP EP17753822.0A patent/EP3416639B1/en active Active
-
2018
- 2018-08-08 IL IL261058A patent/IL261058A/en unknown
- 2018-08-14 CL CL2018002335A patent/CL2018002335A1/es unknown
- 2018-08-15 PH PH12018501731A patent/PH12018501731A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210230180A1 (en) | 2021-07-29 |
| MX2018009952A (es) | 2018-11-29 |
| EP3416639B1 (en) | 2022-06-08 |
| KR20180110132A (ko) | 2018-10-08 |
| CL2018002335A1 (es) | 2019-02-01 |
| IL261058A (en) | 2018-10-31 |
| CA3014791A1 (en) | 2017-08-24 |
| AU2017221404A1 (en) | 2018-08-23 |
| US11111251B2 (en) | 2021-09-07 |
| WO2017143041A1 (en) | 2017-08-24 |
| PH12018501731A1 (en) | 2019-06-17 |
| JP2019504901A (ja) | 2019-02-21 |
| MA44253A (fr) | 2018-12-26 |
| BR112018016689A2 (pt) | 2019-02-12 |
| EP3416639A1 (en) | 2018-12-26 |
| EA201891854A1 (ru) | 2019-01-31 |
| CN109069491A (zh) | 2018-12-21 |
| EP3416639A4 (en) | 2019-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009952A (es) | Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2016002661A1 (es) | Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy. | |
| CL2018002697A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos. | |
| CL2017003127A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico. | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| CO2018013077A2 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas | |
| CL2016000726A1 (es) | Derivados de 4-azaindol | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| MX2016014773A (es) | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico. | |
| CL2016002497A1 (es) | “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct | |
| MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| ECSP17081322A (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
| ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| MX2018002446A (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| BR112018016629A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CL2020000360A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. | |
| CO2019004143A2 (es) | Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa | |
| MX379454B (es) | Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico. | |
| MX2022008016A (es) | Compuesto antagonista de pd-l1. | |
| MX394670B (es) | Agentes anticancerigenos y preparacion de los mismos. |